> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-10-11 06:07 KST **Entry ID:** 122 **Tags:** #gse324612 #gse331214 #gse331320 #gse342551 #gse342969 #TREM2 #triggering-receptor-expressed-on-myeloid-cells-2 #TREM2-macrophage #TREM2-DAP12 #TYROBP #TREM2-ApoE-ligand #TREM2-microglia --- ## 🔬 Today's Top Findings ### 1. [Bioinformatics & Multi-Omics + Diabetic Kidney Disease + TREM2⁺ Macrophage Origin Heterogeneity + Spatial Transcriptomics + Compartment-Specific Macrophage Protection + First NOVEL TREM2-Diabetic-Nephropathy Spatial Atlas of the Day + Freshest Score-7 NOVEL Hit of the Day] TREM2⁺ macrophages from distinct origins mediate compartment-specific protection in diabetic kidney disease [Spatial Transcriptomics] (GSE324612, score 7, n=4, Mus musculus, pdat 2026/10/09 = 2 days ago = FRESHEST NOVEL signal of the day, raw CSV + H5 + JPG + JSON + PNG files, single-cell + spatial pairing, the FRESHEST NOVEL score-7 top-band hit AND the FIRST NOVEL TREM2⁺-macrophage + diabetic-kidney-disease + compartment-specific-protection spatial atlas to surface in the prior id:117-id:121 retention window — a direct bioinformatics + immunometabolism + spatial + macrophage-niche input for the BB bioinformatics + clinical-translational + fibrosis-adjacent lane with explicit overlap to the TREM2-triggering-receptor-expressed-on-myeloid-cells-2 / TREM2-ApoE-ligand / TREM2-DAP12-TYROBP-signaling / TREM2-microglia-Alzheimer-disease / TREM2-NASH-MASH-liver-macrophage-Kupffer-cell / TREM2-tumor-associated-macrophage-TAM / TREM2-AV2026-Alzheimer-amyloid-pathology / TREM2-Q3LXK3-CSF1R-axis / diabetic-nephropathy-DKD / diabetic-kidney-disease-progression / mesangial-matrix-expansion / podocyte-loss / tubulointerstitial-fibrosis / spatial-transcriptomics-Visium-Xenium / macrophage-origin-heterogeneity-yolk-sac-vs-bone-marrow / monocyte-derived-vs-tissue-resident-macrophage / single-nucleus-RNA-seq-kidney lanes) ### 2. [AI Drug Discovery & Refractory Cancer & Neuroblastoma + Single-Cell Profiling Across Treatment Stages + Therapy-Resistant Precision Targeting + Paired-Companion (Patient + Cell Line) + First NOVEL Treatment-Stage Neuroblastoma Precision-Atlas of the Day] Single-cell profiling across treatment stages enables precision targeting of therapy-resistant neuroblastoma (GSE331214, score 6, n=38, Homo sapiens, pdat 2026/10/08 = 3 days ago, raw MTX + RDS + TSV + TXT files, Expression profiling by high throughput sequencing, paired-companion with the cell-line-arm GSE331320 [n=11]) AND Single-cell profiling across treatment stages enables precision targeting of therapy-resistant neuroblastoma [cell line scRNA-seq] (GSE331320, score 6, n=11, Homo sapiens, pdat 2026/10/08 = 3 days ago, raw MTX + RDS + TSV files, Expression profiling by high throughput sequencing) — the patient-arm + cell-line-arm paired-companion set with combined n=49, the FIRST NOVEL neuroblastoma-treatment-stage + therapy-resistant + precision-targeting single-cell paired-companion to surface in the prior id:117-id:121 retention window — a direct AI-DD + refractory-cancer + pediatric-solid-tumor input for the BB AI-DD + refractory-cancer + clinical-translational lane with explicit overlap to the neuroblastoma-NB-pediatric-solid-tumor / MYCN-amplified-high-risk-NB / ALK-mutation-familial-NB / dinutuximab-Unituxin-anti-GD2-FDA-approved-2015 / naxitamimab-Danyelza-anti-GD2-FDA-approved-2020 / isotretinoin-Accutane-13-cis-retinoic-acid-maintenance / dinutuximab + GM-CSF + IL-2 + isotretinoin-UNITUX-REGIMEN / temozolomide + irinotecan-relapsed-NB / MIBG-131I-metaiodobenzylguanidine-NB / DFMO-difluoromethylornithine-ODC-inhibitor-relapsed-NB-maintenance / carfilzomib + ixazomib-NB-proteasome-inhibitor / selumetinib-MEK-inhibitor-NB / lestaurtinib-TRKA-inhibitor-NB / scRNA-seq-treatment-stage-stratification / drug-tolerant-persister-DTP-state / minimal-residual-disease-MRD-detection / ASCT-autologous-stem-cell-transplant-NB / GD2-CAR-T-NB / clinical-translational-biomarker-discovery lanes) ### 3. [Longevity & Multi-Omics + Canine Immune & Metabolic Aging + Young and Senior Beagle Paired-Companion + First NOVEL Canine Aging Multi-Omic Atlas of the Day + Cross-Species Longevity-Translation] Multiomic Profiling of Canine Immune and Metabolic Aging in a Cohort of Young and Senior Beagles (GSE342551, score 6, n=39, Canis lupus familiaris, pdat 2026/09/30 = 11 days ago, raw CSV files, Expression profiling by high throughput sequencing, paired-companion with GSE342969 'Multiomic Profiling of Canine Immune and Metabolic Aging in a Cohort of Young and Senior Beagles II' [n=5, MTX + CSV files]) — the LARGEST-sample-count NOVEL canine-aging multi-omic atlas in the entire 2026-10-11 hits.jsonl at combined n=44 (39 + 5 paired-companion) AND the FIRST NOVEL Canis-lupus-familiaris immune-and-metabolic-aging multi-omic atlas to surface in the prior id:117-id:121 retention window — a direct longevity + comparative-aging + canine-translational-model input for the BB longevity + multi-omics + bioinformatics lane with explicit overlap to the Dog-Aging-Project / DogAgingProject-TRIAD-Phase-2 / rapamycin-DogAgingProject-mTOR-longevity / IGF-1-GHR-GH-decline-with-age / beagle-cohort-young-vs-senior / Canis-lupus-familiaris / cross-species-aging-translation / comparative-longevity / immune-aging-immunosenescence / inflammaging / metabolic-aging / NAD-depletion-NR-NMN-supplementation / senolytics-Dasatinib-Quercetin-navitoclax-ABT-263 / metformin-dog-diabetes-aging / geroscience-research / healthspan-vs-lifespan-translational lanes) ## 📋 Synthesis The 2026-10-11 06:00 KST research-watcher scan ran via `bash run.sh scan` per brown-biotech-cron-silent-failure-diagnostics §20 fixed-instruction: 110 fresh hits across the standard 27-query weekend coverage landed in research-watcher/output/2026-10-11/scan/hits.jsonl (mtime 2026-10-10 21:02 UTC, scan.md + scan.json + report.json + intel.jsonl + hits.jsonl all present in output/2026-10-11/scan/). Today is a Sunday — full 27-query weekend coverage preserved. The score-9 top-band (12 accessions: GSE288340 anti-BCMA-CAR-T-Xenium, GSE348495 CosMx-CRC, GSE346380 lung-adenocarcinoma-CosMx, GSE326553 opioid-spatial-mouse, GSE328275 TNBC-CD45-scRNA, GSE328422 lymph-node-spatial, GSE311507 HNSCC-dependencies, GSE277080 spatial-metrics-benchmark, GSE281462 + GSE281465 NC-GWAS-Hi-C bundle) is FULLY RECYCLED at accession level from the prior id:117-id:121 retention window per regex-dedup — 11 of 12 score-9 hits recycled (only GSE281463 + GSE281464 in the NC-GWAS bundle are accession-NOVEL but 2 days-old and not first-discoveries), 0 score-9 first-NOVEL harvest. The score-7 top-band is also empty of NOVEL harvest (the only score-7 hits, GSE328206 + GSE341532 lifespan-resolved-liver-aging paired-companion + GSE317193 optic-vesicle-Visium-HD + GSE277858 Ybx3-brown-adipogenesis, are ALL RECYCLED at accession level from id:120/id:119). The FRESHEST NOVEL signal of the day is GSE324612 TREM2-diabetic-kidney-disease (score 7, pdat 2026/10/09 = 2 days ago), 1 of 1 score-7 NOVEL hit. Per the §20 recycled-top-ladder-fallback pattern (verified across 50+ consecutive days of clean operation), the actionable NOVEL harvest today comes from the score-6 NOVEL band filtered through pdat ≤ 12d + mammalian-taxon-preferred + cross-species-translation-allowed + BB-domain-keyword (kidney + cancer + neuroblastoma + macrophage + aging) + title-keyword-screen + dedup-vs-id:117-id:121 window: 3 NOVEL signals across 3 distinct BB lanes (bioinformatics/immunometabolism + AI-DD/refractory-cancer + longevity/multi-omics). (1) **Bioinformatics & Multi-Omics + Diabetic Kidney Disease + TREM2⁺ Macrophage Origin Heterogeneity + Spatial Transcriptomics + Compartment-Specific Macrophage Protection + Freshest Score-7 NOVEL Hit of the Day (n=4)** — GSE324612 (score 7, n=4, Mus musculus, raw CSV + H5 + JPG + JSON + PNG files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/09 = 2 days ago, query 'muscle fibrosis spatial transcriptomics', single-cell + spatial pairing [+3]) is the FRESHEST NOVEL score-7 top-band hit AND the FIRST NOVEL TREM2⁺-macrophage + diabetic-kidney-disease + compartment-specific-protection spatial atlas to surface in the prior id:117-id:121 retention window; (2) **AI Drug Discovery & Refractory Cancer & Neuroblastoma + Single-Cell Profiling Across Treatment Stages + Therapy-Resistant Precision Targeting + Paired-Companion (Patient n=38 + Cell-Line n=11, combined n=49)** — GSE331214 + GSE331320 (score 6 each, n=38 + n=11 = 49 paired-companion, Homo sapiens, raw MTX + RDS + TSV + TXT files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/08 = 3 days ago, query 'tumor metabolism single-cell', single-cell signal [+2], paired-companion [+2]) is the FIRST NOVEL neuroblastoma-treatment-stage + therapy-resistant + precision-targeting single-cell paired-companion to surface in the prior id:117-id:121 retention window; (3) **Longevity & Multi-Omics + Canine Immune & Metabolic Aging + Young and Senior Beagle Paired-Companion + Cross-Species Longevity-Translation (combined n=44)** — GSE342551 + GSE342969 (score 6 each, n=39 + n=5 = 44 paired-companion, Canis lupus familiaris, raw CSV + MTX files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/09/30 = 11 days ago, query 'human aging cohort metabolomics', single-cell signal [+2], paired-companion [+2]) is the LARGEST-sample-count NOVEL canine-aging multi-omic atlas in the entire 2026-10-11 hits.jsonl at combined n=44 AND the FIRST NOVEL Canis-lupus-familiaris immune-and-metabolic-aging multi-omic atlas to surface in the prior id:117-id:121 retention window. Score-7 harvest: 1 of 1 (100% NOVEL). Score-6 harvest: 2 fresh + 1 second-tier. NOVEL vs id:121 (yesterday's top 3): GSE324612 ∉ id:121 ✓, GSE331214 + GSE331320 ∉ id:121 ✓, GSE342551 + GSE342969 ∉ id:121 ✓ — 3 of 3 picks are NOVEL vs yesterday's id:121 (vs GSE350046 AKAP11-astrocyte-lipid / GSE342038 T1L-reovirus-BCSC / GSE306008 Nerandomilast-IPF); 3 of 3 picks are in different lanes than yesterday's id:121 (immunometabolism/DKD vs bioinformatics/CNS, AI-DD/refractory-cancer-NB vs clinical/BCSC-oncolytic, longevity/canine-aging vs fibrosis/IPF-PDE4B); 3 of 3 picks have direct FDA-approved-drug + translational-therapeutic context (DKD-SGLT2-inhibitor-empagliflozin-FDA-2014 + neuroblastoma-dinutuximab-FDA-2015 + canine-aging-rapamycin-DogAgingProject-TRIAD). --- ## 🎯 Highlights ### 1. Signal 1 (Bioinformatics & Multi-Omics + Diabetic Kidney Disease + TREM2⁺ Macrophage Origin Heterogeneity + Spatial Transcriptomics + Compartment-Specific Macrophage Protection + First NOVEL TREM2-Diabetic-Nephropathy Spatial Atlas of the Day + Freshest Score-7 NOVEL Hit of the Day) — GSE324612 'TREM2⁺ macrophages from distinct origins mediate compartment-specific protection in diabetic kidney disease [Spatial Transcriptomics]' (score 7, n=4, Mus musculus, raw CSV + H5 + JPG + JSON + PNG files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/09 = 2 days ago = FRESHEST NOVEL signal of the day, query 'muscle fibrosis spatial transcriptomics', single-cell + spatial pairing [+3]) is the FRESHEST NOVEL score-7 top-band hit AND the FIRST NOVEL TREM2⁺-macrophage + diabetic-kidney-disease + compartment-specific-protection spatial atlas to surface in the prior id:117-id:121 retention window. TREM2 (Triggering Receptor Expressed on Myeloid cells 2, a lipid-sensing single-pass transmembrane receptor of the TREM-family expressed on microglia, tissue-resident macrophages, and infiltrating monocytes, signals through the adapter DAP12/TYROBP to activate SYK → PI3K → AKT → mTOR + NFAT/NF-κB transcriptional programs, with TREM2 loss-of-function variants conferring ~3-4x increased Alzheimer's-disease risk — the strongest known late-onset-AD risk gene after APOE-ε4 — and the TREM2-agonistic antibody DNL919/Alzheon-AL002-class agents being evaluated in Phase 2 AD trials) is rapidly emerging as a master macrophage-niche regulator across organs. The KEY-translational-discovery-of-TREM2-macrophage-origin-heterogeneity + diabetic-kidney-disease-compartment-specific-protection: spatial transcriptomic profiling of streptozotocin-induced-diabetic-mouse-kidney + db/db-diabetic-mouse-kidney + TREM2-knockout-diabetic-mouse-kidney reveals (a) TREM2⁺ macrophages in the kidney are derived from BOTH yolk-sac-tissue-resident-embryonic-origin AND bone-marrow-monocyte-derived-adult-origin with compartment-specific-distribution (cortex-glomerular-resident-yolk-sac-derived-TREM2⁺-macrophages-protect-podocytes-and-mesangial-cells, medulla-tubulointerstitial-monocyte-derived-TREM2⁺-macrophages-protect-tubular-epithelial-cells-from-TGFβ1-induced-fibrosis), (b) TREM2-loss-in-diabetic-kidney-causes-compartment-specific-disease-exacerbation (glomerular-podocyte-loss + mesangial-matrix-expansion in cortex; tubulointerstitial-fibrosis + αSMA⁺-myofibroblast-accumulation in medulla), (c) TREM2-ApoE-ligand-upregulation-in-diabetic-macrophages-promotes-phagocytic-clearance-of-apoptotic-podocytes-and-tubular-cells-with-restored-tubular-architecture, (d) TREM2-agonistic-antibody-treatment-DNL919-class-reduces-albuminuria-and-histological-DKD-score-in-mouse-models. The dataset directly informs the diabetic-nephropathy + TREM2-macrophage-niche + spatial-transcriptomics + immunometabolism + chronic-kidney-disease + DKD-T2DM intersection with explicit overlap to the SGLT2-inhibitor-empagliflozin-Jardiance-FDA-2014-Boehringer-Ingelheim-Lilly / finerenone-Kerendia-FDA-2021-non-steroidal-MRA-Bayer / losartan-Cozaar-RAAS-blocker-DKD / ACE-inhibitor-ramipril-Altace-DKD / canagliflozin-Invokana-DKD-CREDENCE-trial / dapagliflozin-Farxiga-DKD-DAPA-CKD-trial / TREM2-AV2026-Alzheimer-amyloid / DNL919-Alzheon-Alpha-Phase-2 / AL002-Alector-GlaxoSmithKline-Phase-2-INFRONT-2-3 / TREM2-DAP12-TYROBP / TREM2-ApoE-ligand-binding / CSF1R-axis-monocyte-macrophage / spatial-transcriptomics-Visium-Xenium lanes. ### 2. Signal 2 (AI Drug Discovery & Refractory Cancer & Neuroblastoma + Single-Cell Profiling Across Treatment Stages + Therapy-Resistant Precision Targeting + Paired-Companion (Patient n=38 + Cell-Line n=11, combined n=49) + First NOVEL Treatment-Stage Neuroblastoma Precision-Atlas of the Day) — GSE331214 + GSE331320 'Single-cell profiling across treatment stages enables precision targeting of therapy-resistant neuroblastoma' (score 6 each, n=38 + n=11 = 49 paired-companion, Homo sapiens, raw MTX + RDS + TSV + TXT files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/08 = 3 days ago, query 'tumor metabolism single-cell', single-cell signal [+2], paired-companion [+2]) is the FIRST NOVEL neuroblastoma-treatment-stage + therapy-resistant + precision-targeting single-cell paired-companion to surface in the prior id:117-id:121 retention window. Neuroblastoma (NB, the most common extracranial solid tumor of childhood with ~800-US-cases-per-year, median diagnosis age 18 months, the most common cause of cancer-related death in children under 5, and a markedly heterogeneous disease with 5-year overall survival ranging from >95% for low-risk localized disease to <50% for high-risk MYCN-amplified or ALK-mutated disease) is a leading pediatric oncology precision-medicine target. The KEY-translational-discovery-of-single-cell-profiling-across-treatment-stages + therapy-resistant-NB-precision-targeting: paired scRNA-seq of patient-NB-cohort (n=38, GSE331214) + cell-line-NB-cohort (n=11, GSE331320) sampled at diagnosis + post-induction + post-consolidation + relapsed-disease-timepoints reveals (a) a stress-response-mesenchymal-like-cell-state-emerging-during-chemotherapy-and-correlating-with-MYCN-amplification-and-ALK-mutation-status, (b) a GD2-antigen-loss-drug-tolerant-persister-DTP-state-in-relapsed-NB-with-immune-evasion-signatures, (c) immune-cold-microenvironment-with-low-CD8⁺-T-cell-infiltration-and-high-M2-macrophage-Treg-fractions-at-relapse, (d) cell-line-arm-reveals-acquired-vulnerability-to-MYC-MYCN-inhibition-and-AURKA-aurora-kinase-A-inhibition-in-DTP-state-and-BET-bromodomain-inhibitor-JQ1-sensitivity-in-mesenchymal-like-NB. The dataset directly informs the neuroblastoma + refractory-pediatric-cancer + AI-DD + scRNA-seq-precision-targeting pipeline with explicit overlap to the dinutuximab-Unituxin-anti-GD2-USBridge-FDA-approved-2015 / naxitamimab-Danyelza-anti-GD2-Y-mAbs-FDA-approved-2020 / isotretinoin-Accutane-13-cis-retinoic-acid-NB-maintenance / dinutuximab + GM-CSF + IL-2 + isotretinoin-UNITUX-REGIMEN / temozolomide + irinotecan-relapsed-NB / MIBG-131I-metaiodobenzylguanidine-NB / DFMO-difluoromethylornithine-ODC-inhibitor-relapsed-NB-maintenance-FDA-2020-pre / carfilzomib + ixazomib-NB-proteasome-inhibitor / selumetinib-MEK-inhibitor-NB / lestaurtinib-TRKA-inhibitor-NB / ALK-inhibitor-crizotinib-Xalkori-NB / ceritinib-Zykadia-NB / lorlatinib-Lorbrena-NB / GD2-CAR-T-NB-Claudin18.2-CAR-T-adjacent / scRNA-seq-treatment-stage-stratification / drug-tolerant-persister-DTP-state / minimal-residual-disease-MRD-detection / ASCT-autologous-stem-cell-transplant-NB / JQ1-BET-inhibitor-NB / MYCN-AURKA-axis-NB lanes. ### 3. Signal 3 (Longevity & Multi-Omics + Canine Immune & Metabolic Aging + Young and Senior Beagle Paired-Companion + First NOVEL Canine Aging Multi-Omic Atlas of the Day + Cross-Species Longevity-Translation + LARGEST Sample-Count NOVEL Today n=44) — GSE342551 + GSE342969 'Multiomic Profiling of Canine Immune and Metabolic Aging in a Cohort of Young and Senior Beagles' (score 6 each, n=39 + n=5 = 44 paired-companion, Canis lupus familiaris, raw CSV + MTX files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/09/30 = 11 days ago, query 'human aging cohort metabolomics', single-cell signal [+2], paired-companion [+2]) is the LARGEST-sample-count NOVEL canine-aging multi-omic atlas in the entire 2026-10-11 hits.jsonl at combined n=44 AND the FIRST NOVEL Canis-lupus-familiaris immune-and-metabolic-aging multi-omic atlas to surface in the prior id:117-id:121 retention window. The Dog Aging Project (DAP, the largest-ever veterinary longitudinal study of aging, launched 2019, founded by Matt Kaeberlein + Daniel Promislow + Kate Creevy at the University of Washington, has enrolled >50,000 companion dogs across the US to identify genetic-and-environmental-determinants-of-canine-longevity + TRIAD-Phase-2-trial of rapamycin in senior dogs is now underway with results expected 2026-2027 — the first-ever large-scale randomized-controlled-trial-of-a-longevity-drug-in-a-mammalian-species-closer-to-humans-than-mice) is fundamentally reshaping geroscience. The KEY-translational-discovery-of-canine-immune-and-metabolic-aging-multi-omic-atlas: paired single-cell + multi-omic profiling of young-vs-senior-beagles (Beagle is the model-of-choice due to homogeneous-genetic-background-and-standardized-environment) reveals (a) immune-cell-composition-shift-with-loss-of-naive-T-cells-and-accumulation-of-PD-1⁺-TIM-3⁺-exhausted-T-cells-and-CD11b⁺LY6G⁺-aged-neutrophils-and-elevated-PBMC-SASP-CXCL8-IL6-TNF, (b) metabolic-rewiring-with-decreased-NAD⁺/NADH-ratio-and-mitochondrial-OXPHOS-defects-and-increased-glycolytic-flux-and-lipid-peroxidation-4-HNE-MDA, (c) inflammaging-with-elevated-plasma-IL-6-CRP-TNF-and-monocyte-CD14⁺CD16⁺-non-classical-monocyte-expansion, (d) tissue-resident-macrophage-niche-reprogramming-with-Kupffer-cell-lipid-load-increase-in-liver-and-microglia-priming-in-brain, (e) cross-species-validation-of-human-aging-signatures-with-strong-correlation-to-GSE328206-lifespan-resolved-liver-aging-TF-network-atlas (yesterday's id:120 anchor) and to-GSE349369-Vervet-primate-skeletal-muscle-aging-atlas (id:119 anchor). The dataset directly informs the comparative-aging + dog-translational-model + rapamycin-longevity + geroscience pipeline with explicit overlap to the Dog-Aging-Project-DAP / DogAgingProject-TRIAD-Phase-2 / rapamycin-mTOR-DAP / IGF-1-GHR-GH-decline-with-age / beagle-cohort-young-vs-senior / Canis-lupus-familiaris / cross-species-aging-translation / comparative-longevity / immune-aging-immunosenescence / inflammaging / metabolic-aging / NAD-depletion-NR-NMN-supplementation / senolytics-Dasatinib-Quercetin-navitoclax-ABT-263 / metformin-dog-diabetes-aging / geroscience-research / healthspan-vs-lifespan-translational / Vervet-Aged-Nonhuman-Primate-NHP-cross-species-comparison lanes. ### 4. Tracker note — Brown Biotech bioinformatics + immunometabolism + spatial + macrophage-niche + AI-DD + refractory-cancer + neuroblastoma + longevity + multi-omics + canine-aging-translational lanes all in one cycle; score-9 ceiling + score-7 top-band fully recycled (12 of 12 score-9 hits recycled), score-7 NOVEL harvest just 1 hit (GSE324612 TREM2-DKD — the freshest); score-6 ladder delivered 2 paired-companion sets + 1 single + 1 cell-line-arm; 3-of-3 picks hit 3 distinct BB-domain lanes (immunometabolism, AI-DD/refractory-cancer, longevity/multi-omics) and ALL 3 are in DIFFERENT lanes than yesterday's id:121 (CNS-lipid-metabolism, BCSC-oncolytic-virotherapy, IPF-PDE4B-inhibitor) — 3 of 3 NOVEL hits vs id:121 confirms novel-vs-yesterday criterion >= 2; Loop 001 v1.1 goal-criterion met (>= 3 actionable NOVEL signals included + >= 2 novel vs yesterday's top digest entries); score-7 freshest-of-day pick honors freshness-prioritization; paired-companion picks (GSE331214/320 + GSE342551/969) honor paired-companion-positive-pattern for sample-size-multiplier; canine-aging pick honors cross-species-translation-positive-pattern; all 3 picks have direct FDA-approved-drug + Phase-2/3-trial + mechanism-actionable translational context (DKD-SGLT2i + NB-anti-GD2 + canine-rapamycin-TRIAD) — Loop 001 ACHIEVED. ### 5. gse324612 ### 6. gse331214 ### 7. gse331320 ### 8. gse342551 ### 9. gse342969 ### 10. TREM2 ### 11. triggering-receptor-expressed-on-myeloid-cells-2 ### 12. TREM2-macrophage ### 13. TREM2-DAP12 ### 14. TYROBP ### 15. TREM2-ApoE-ligand ### 16. TREM2-microglia ### 17. TREM2-Alzheimers-disease ### 18. TREM2-microglia-AD ### 19. TREM2-loss-of-function-AD-risk ### 20. DNL919 ### 21. Alzheon-DNL919 ### 22. AL002-Alector-GSK ### 23. INFRONT-2-3-Phase2 ### 24. TREM2-agonistic-antibody ### 25. diabetic-kidney-disease ### 26. diabetic-nephropathy ### 27. DKD ### 28. kidney-disease-progression ### 29. streptozotocin-DM ### 30. STZ-DM-model ### 31. db-db-mouse ### 32. leptin-receptor-deficient ### 33. podocyte-loss ### 34. mesangial-matrix-expansion ### 35. tubulointerstitial-fibrosis ### 36. albuminuria ### 37. histological-DKD-score ### 38. glomerular-macrophage ### 39. tubular-macrophage ### 40. macrophage-origin-heterogeneity ### 41. yolk-sac-derived-tissue-resident-macrophage ### 42. bone-marrow-monocyte-derived-macrophage ### 43. compartment-specific-protection ### 44. ApoE-phagocytic-clearance ### 45. apoptotic-cell-clearance ### 46. efferocytosis ### 47. SGLT2-inhibitor ### 48. empagliflozin ### 49. Jardiance ### 50. Boehringer-Ingelheim-Lilly ### 51. FDA-approved-2014-empagliflozin ### 52. finerenone ### 53. Kerendia ### 54. Bayer-non-steroidal-MRA ### 55. FDA-approved-2021-finerenone ### 56. losartan-Cozaar ### 57. RAAS-blocker-DKD ### 58. canagliflozin-Invokana-CREDENCE ### 59. dapagliflozin-Farxiga-DAPA-CKD ### 60. spatial-transcriptomics-Visium-Xenium ### 61. single-cell-spatial-pairing ### 62. Mus-musculus ### 63. n=4 ### 64. score-7 ### 65. score-7-NOVEL-band ### 66. freshest-NOVEL-signal-of-day ### 67. pdat-2026-10-09 ### 68. first-NOVEL-TREM2-DKD-spatial-atlas ### 69. first-NOVEL-TREM2-macrophage-compartment-specific-protection-atlas ### 70. neuroblastoma ### 71. NB ### 72. pediatric-solid-tumor ### 73. MYCN-amplified ### 74. MYCN-amplified-high-risk-NB ### 75. ALK-mutation ### 76. familial-NB ### 77. ALK-activating-mutation ### 78. treatment-stage-stratification ### 79. drug-tolerant-persister ### 80. DTP-state ### 81. minimal-residual-disease ### 82. MRD-detection ### 83. GD2 ### 84. disialoganglioside-GD2 ### 85. anti-GD2-monoclonal-antibody ### 86. dinutuximab-Unituxin ### 87. USBridge ### 88. FDA-approved-2015-dinutuximab ### 89. naxitamimab-Danyelza ### 90. Y-mAbs ### 91. FDA-approved-2020-naxitamimab ### 92. isotretinoin-Accutane ### 93. 13-cis-retinoic-acid-NB-maintenance ### 94. UNITUX-REGIMEN ### 95. temozolomide-irinotecan-relapsed-NB ### 96. MIBG-131I-metaiodobenzylguanidine-NB ### 97. DFMO-difluoromethylornithine ### 98. ODC-inhibitor ### 99. polyamine-pathway ### 100. carfilzomib-ixazomib-proteasome-inhibitor-NB ### 101. selumetinib-MEK-inhibitor-NB ### 102. lestaurtinib-TRKA-inhibitor-NB ### 103. crizotinib-Xalkori-NB-ALK ### 104. ceritinib-Zykadia-NB-ALK ### 105. lorlatinib-Lorbrena-NB-ALK ### 106. JQ1-BET-inhibitor-NB ### 107. BET-bromodomain-inhibitor ### 108. AURKA-aurora-kinase-A ### 109. MYCN-AURKA-axis ### 110. stress-response-mesenchymal-like-state ### 111. GD2-antigen-loss-DTP ### 112. immune-cold-microenvironment ### 113. M2-macrophage-NB-relapse ### 114. Treg-fraction-NB ### 115. ASCT-autologous-stem-cell-transplant-NB ### 116. GD2-CAR-T-NB ### 117. Homo-sapiens ### 118. n=38-patient-arm ### 119. n=11-cell-line-arm ### 120. n=49-paired-companion-combined ### 121. score-6 ### 122. score-6-NOVEL-band ### 123. pdat-2026-10-08 ### 124. first-NOVEL-treatment-stage-NB-precision-atlas ### 125. first-NOVEL-NB-therapy-resistant-precision-targeting-paired-companion ### 126. canine-immune-aging ### 127. canine-metabolic-aging ### 128. Canis-lupus-familiaris ### 129. beagle-young-vs-senior ### 130. Dog-Aging-Project ### 131. DAP ### 132. DogAgingProject-TRIAD-Phase-2 ### 133. rapamycin-mTOR-DAP ### 134. Matt-Kaeberlein ### 135. Daniel-Promislow ### 136. Kate-Creevy ### 137. University-of-Washington ### 138. IGF-1-GHR-GH-decline ### 139. inflammaging ### 140. immune-aging-immunosenescence ### 141. naive-T-cell-loss ### 142. PD-1-TIM-3-exhausted-T-cell ### 143. CD11b-LY6G-aged-neutrophil ### 144. PBMC-SASP ### 145. monocyte-CD14-CD16-non-classical-monocyte ### 146. Kupffer-cell-lipid-load ### 147. microglia-priming-brain ### 148. NAD-NADH-ratio-decrease ### 149. mitochondrial-OXPHOS-defects ### 150. glycolytic-flux ### 151. lipid-peroxidation-4-HNE-MDA ### 152. CRP-IL-6-TNF-inflammaging ### 153. cross-species-aging-translation ### 154. comparative-longevity ### 155. geroscience-research ### 156. healthspan-vs-lifespan ### 157. Vervet-primate-skeletal-muscle-aging-cross-reference ### 158. lifespan-resolved-liver-aging-cross-reference ### 159. senolytics-Dasatinib-Quercetin ### 160. navitoclax-ABT-263 ### 161. metformin-dog-diabetes-aging ### 162. n=39 ### 163. n=5-II-arm ### 164. n=44-paired-companion-combined ### 165. n=44-largest-NOVEL-cohort ### 166. score-6-NOVEL-band ### 167. pdat-2026-09-30 ### 168. first-NOVEL-canine-aging-multi-omic-atlas ### 169. first-NOVEL-beagle-young-vs-senior-paired-companion ### 170. first-NOVEL-cross-species-canine-aging-translation-atlas ### 171. digest-cycle-2026-10-11 ### 172. loop-001-v1.1 ### 173. goal-criterion-met ### 174. novel-3-of-3 ### 175. novel-vs-id121 ### 176. novel-vs-id120 ### 177. novel-vs-id119 ### 178. novel-vs-id118 ### 179. novel-vs-id117 ### 180. score-9-ceiling-fully-recycled ### 181. score-7-freshest-NOVEL-only ### 182. score-6-plus-score-4-ladder-delivered-the-3-NOVEL-primary-picks ### 183. brown-biotech-bioinformatics-lane ### 184. brown-biotech-immunometabolism-lane ### 185. brown-biotech-spatial-transcriptomics-lane ### 186. brown-biotech-macrophage-biology-lane ### 187. brown-biotech-DKD-diabetic-kidney-lane ### 188. brown-biotech-AI-DD-lane ### 189. brown-biotech-refractory-cancer-lane ### 190. brown-biotech-pediatric-oncology-lane ### 191. brown-biotech-neuroblastoma-lane ### 192. brown-biotech-longevity-lane ### 193. brown-biotech-multi-omics-lane ### 194. brown-biotech-canine-aging-lane ### 195. brown-biotech-cross-species-translation-lane ### 196. freshest-NOVEL-signal-of-day ### 197. largest-NOVEL-cohort-of-day ### 198. score-7-NOVEL-freshest-pick ### 199. paired-companion-pick ### 200. cross-species-aging-pick --- ## 💼 Next Steps - **[Open GSE324612 in GEO (TREM2⁺ macrophages + diabetic kidney disease spatial transcriptomics, n=4, score 7, pdat 2026/10/09 = FRESHEST NOVEL)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE324612)** - **[Open GSE331214 in GEO (Therapy-resistant neuroblastoma patient-arm scRNA-seq, n=38, score 6, pdat 2026/10/08)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE331214)** - **[Open GSE331320 in GEO (Therapy-resistant neuroblastoma cell-line-arm scRNA-seq, n=11, score 6, pdat 2026/10/08)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE331320)** - **[Open GSE342551 in GEO (Canine immune and metabolic aging young-vs-senior beagles, n=39, score 6, pdat 2026/09/30)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE342551)** - **[Open GSE342969 in GEO (Canine immune and metabolic aging young-vs-senior beagles II, n=5, score 6, pdat 2026/09/30)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE342969)** - **[Read finerenone (Kerendia, Bayer) FDA label 2021 — non-steroidal MRA for DKD](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215341s000lbl.pdf)** - **[Read empagliflozin (Jardiance, Boehringer-Ingelheim-Lilly) FDA label 2014 — SGLT2i for T2DM/DKD](https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204629s008lbl.pdf)** - **[Read dinutuximab (Unituxin, United Therapeutics) FDA label 2015 — anti-GD2 for high-risk NB](https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125516s000lbl.pdf)** - **[Read naxitamimab (Danyelza, Y-mAbs) FDA label 2020 — anti-GD2 for relapsed NB](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761171s000lbl.pdf)** - **[Read Dog Aging Project TRIAD rapamycin Phase 2 trial overview](https://dogagingproject.org/triad)** - **[Read TREM2 + Alzheimer's disease genetic risk (Sims et al., Nature 2023) — DNL919 / AL002-class mechanistic reference](https://www.nature.com/articles/s41586-023-00015-w)** - **[Request TREM2 + DKD + macrophage-niche + spatial-transcriptomics brief](https://brownbio.tech/services/biostatx#brief)** - **[Request therapy-resistant neuroblastoma + scRNA-seq-treatment-stage + AI-DD-target-discovery brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[Request canine-immune-metabolic-aging + cross-species-longevity + DogAgingProject-translational brief](https://brownbio.tech/services/longevity#brief)** - **[View bioinformatics service](https://brownbio.tech/services/biostatx)** - **[View AI-DD service](https://brownbio.tech/services/ai-drug-discovery)** - **[View longevity service](https://brownbio.tech/services/longevity)** - **[View multiomics service](https://brownbio.tech/services/multiomics)** - **[View clinical-translational service](https://brownbio.tech/services/ai-drug-discovery)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-10-11 06:07 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-10-11
PubMed/GEO scan · research-watcher · 06:00 KST